Regeneron Pharmaceuticals Inc (REGN) support and resistance · P/E 14, rev $14.34B
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
This page maps Regeneron Pharmaceuticals Inc (REGN) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new REGN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the REGN quote page for the session range and the stock page for the full model.
Not investment advice.